Kynurenic acid and psychotic symptoms and personality traits in twins with psychiatric morbidity

Psychiatry Research

Volumn 247, Issue , 2017, Pages 105-112

  Kegel, Magdalena E ^a   Johansson, Viktoria ^a   Wetterberg, Lennart ^a   Bhat, Maria ^b   Schwieler, Lilly ^a   Cannon, Tyrone D ^c   Schuppe Koistinen, Ina ^a,d   Engberg, Göran ^a   Landén, Mikael ^a,e   Hultman, Christina M ^a   Erhardt, Sophie ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Protein Biomarkers Personalized Healthcare Biomarker Laboratories Innovative Medicines   (Sweden)

^c YALE UNIVERSITY   (United States)

^d ASTRAZENECA   (United Kingdom)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Bipolar disorder; Cerebrospinal fluid; Kynurenic acid; Neuroinflammation; Schizophrenia; Twin studies

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 8; KYNURENIC ACID; QUINOLINIC ACID; TRYPTOPHAN; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; BIPOLAR DISORDER; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; FEMALE; GENETIC ASSOCIATION; HUMAN; MALE; MENTAL DISEASE ASSESSMENT; MORBIDITY; PERSONALITY; PRIORITY JOURNAL; SCALES FOR ASSESSMENT OF NEGATIVE AND POSITIVE SYMPTOM; SCHIZOPHRENIA; SCHIZOTYPAL PERSONALITY QUESTIONNAIRE BRIEF; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; TWINS; CEREBROSPINAL FLUID; COMPLICATION; MIDDLE AGED; PSYCHOLOGY; PSYCHOSIS;

BIPOLAR DISORDER; FEMALE; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; KYNURENIC ACID; MALE; MIDDLE AGED; PERSONALITY; PSYCHOTIC DISORDERS; QUINOLINIC ACID; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TRYPTOPHAN; TUMOR NECROSIS FACTOR-ALPHA; TWINS;

EID: 84996636708     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2016.11.017     Document Type: Article

References (46)

1. Andreasen, N.C., Scale for the Assessment of Negative Symptoms (SANS). 1983, University of Iowa, Iowa City.
2. Andreasen, N.C., The scale for the Assessment of Positive Symptoms (SAPS). 1984, University of Iowa, Iowa City.
3. Baron, M., Gruen, R., Rainer, J.D., Kane, J., Asnis, L., Lord, S., A family study of schizophrenic and normal control probands: implications for the spectrum concept of schizophrenia. Am. J. Psychiatry 142:4 (1985), 447–455.
4. Brodin, P., Jojic, V., Gao, T., Bhattacharya, S., Angel, C.J., Furman, D., Shen-Orr, S., Dekker, C.L., Swan, G.E., Butte, A.J., Maecker, H.T., Davis, M.M., Variation in the human immune system is largely driven by non-heritable influences. Cell 160:1–2 (2015), 37–47.
5. Croitoru-Lamoury, J., Guillemin, G.J., Boussin, F.D., Mognetti, B., Gigout, L.I., Cheret, A., Vaslin, B., Le Grand, R., Brew, B.J., Dormont, D., Expression of chemokines and their receptors in human and simian astrocytes: evidence for a central role of TNF alpha and IFN gamma in CXCR4 and CCR5 modulation. Glia 41:4 (2003), 354–370.
6. Croitoru-Lamoury, J., Guillemin, G.J., Dormont, D., Brew, B.J., Quinolinic acid up-regulates chemokine production and chemokine receptor expression in astrocytes. Adv. Exp. Med Biol. 527 (2003), 37–45.
7. de Jager, W., Bourcier, K., Rijkers, G.T., Prakken, B.J., Seyfert-Margolis, V., Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays. BMC Immunol., 10, 2009, 52.
8. Erhardt, S., Blennow, K., Nordin, C., Skogh, E., Lindstrom, L.H., Engberg, G., Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci. Lett. 313:1–2 (2001), 96–98.
9. Erhardt, S., Olsson, S.K., Engberg, G., Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders. CNS Drugs 23:2 (2009), 91–101.
10. Erhardt, S., Schwieler, L., Imbeault, S., Engberg, G., The kynurenine pathway in schizophrenia and bipolar disorder. Neuropharmacology, 2016.
11. First, M.B., Gibbon, M., Spitzer, R.L., Williams, J.B.W., Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I), Clinical Version. 1997, American Psychiatric Press, Washington D.C.
12. First, M.B., Gibbon, M., Spitzer, R.L., Williams, J.B.W., Benjamin, L.S., Structured Clinical Interview for DSM-IV Axis II Personality Disorders, (SCID-II). 1997, American Psychiatric Press, Inc., Washington, D.C.
13. Gottesman, I.I., Gould, T.D., The endophenotype concept in psychiatry: etymology and strategic intentions. Am. J. Psychiatry 160:4 (2003), 636–645.
14. Hannelius, U., Population genetic, association and zygosity testing on preamplified DNA, Department of Nutrition and Biosciences. 2008, Karolinska Institutet, Stockholm, 60.
15. Isgren, A., Jakobsson, J., Palsson, E., Ekman, C.J., Johansson, A.G., Sellgren, C., Blennow, K., Zetterberg, H., Landen, M., Increased cerebrospinal fluid interleukin-8 in bipolar disorder patients associated with lithium and antipsychotic treatment. Brain Behav. Immun. 43 (2015), 198–204.
16. Johansson, V., Nybom, R., Wetterberg, L., Hultman, C.M., Cannon, T.D., Johansson, A.G., Ekman, C.J., Landen, M., Microscopic particles in two fractions of fresh cerebrospinal fluid in twins with schizophrenia or bipolar disorder and in healthy controls. PLoS One, 7(9), 2012, e45994.
17. Kendler, K.S., McGuire, M., Gruenberg, A.M., Walsh, D., Schizotypal symptoms and signs in the Roscommon Family Study. Their factor structure and familial relationship with psychotic and affective disorders. Arch. Gen. Psychiatry 52:4 (1995), 296–303.
18. King, N.J., Thomas, S.R., Molecules in focus: indoleamine 2,3-dioxygenase. Int J. Biochem Cell Biol. 39:12 (2007), 2167–2172.
19. Lavebratt, C., Olsson, S., Backlund, L., Frisen, L., Sellgren, C., Priebe, L., Nikamo, P., Traskman-Bendz, L., Cichon, S., Vawter, M.P., Osby, U., Engberg, G., Landen, M., Erhardt, S., Schalling, M., The KMO allele encoding Arg452 is associated with psychotic features in bipolar disorder type 1, and with increased CSF KYNA level and reduced KMO expression. Mol. Psychiatry 19:3 (2014), 334–341.
20. Linderholm, K.R., Skogh, E., Olsson, S.K., Dahl, M.L., Holtze, M., Engberg, G., Samuelsson, M., Erhardt, S., Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr. Bull. 38:3 (2012), 426–432.
21. Mandi, Y., Vecsei, L., The kynurenine system and immunoregulation. J. Neural Transm. (Vienna) 119:2 (2012), 197–209.
22. Miller, B.J., Buckley, P., Seabolt, W., Mellor, A., Kirkpatrick, B., Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 70:7 (2011), 663–671.
23. Miller, C.L., Llenos, I.C., Dulay, J.R., Weis, S., Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res 1073–1074 (2006), 25–37.
24. Mobarrez, F., Nybom, R., Johansson, V., Hultman, C.M., Wallen, H., Landen, M., Wetterberg, L., Microparticles and microscopic structures in three fractions of fresh cerebrospinal fluid in schizophrenia: case report of twins. Schizophr. Res. 143:1 (2013), 192–197.
25. Nilsson, L.K., Linderholm, K.R., Engberg, G., Paulson, L., Blennow, K., Lindstrom, L.H., Nordin, C., Karanti, A., Persson, P., Erhardt, S., Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr. Res. 80:2–3 (2005), 315–322.
26. Olsson, S.K., Samuelsson, M., Saetre, P., Lindstrom, L., Jonsson, E.G., Nordin, C., Engberg, G., Erhardt, S., Landen, M., Elevated levels of kynurenic acid in the cerebrospinal fluid of patients with bipolar disorder. J. Psychiatry Neurosci. 35:3 (2010), 195–199.
27. Olsson, S.K., Sellgren, C., Engberg, G., Landen, M., Erhardt, S., Cerebrospinal fluid kynurenic acid is associated with manic and psychotic features in patients with bipolar I disorder. Bipolar Disord. 14:7 (2012), 719–726.
28. Pemberton, L.A., Kerr, S.J., Smythe, G., Brew, B.J., Quinolinic acid production by macrophages stimulated with IFN-gamma, TNF-alpha, and IFN-alpha. J. Interferon Cytokine Res. 17:10 (1997), 589–595.
29. Raine, A., The SPQ: a scale for the assessment of schizotypal personality based on DSM-III-R criteria. Schizophr. Bull. 17:4 (1991), 555–564.
30. Raine, A., Benishay, D., The SPQ-B: a Brief screening instrument for Schizotypal personality disorder. J. Personal. Disord. 9:4 (1995), 346–355.
31. Sas, A.A., Jamshidi, Y., Zheng, D., Wu, T., Korf, J., Alizadeh, B.Z., Spector, T.D., Snieder, H., The age-dependency of genetic and environmental influences on serum cytokine levels: a twin study. Cytokine 60:1 (2012), 108–113.
32. Sasayama, D., Hattori, K., Wakabayashi, C., Teraishi, T., Hori, H., Ota, M., Yoshida, S., Arima, K., Higuchi, T., Amano, N., Kunugi, H., Increased cerebrospinal fluid interleukin-6 levels in patients with schizophrenia and those with major depressive disorder. J. Psychiatr. Res. 47:3 (2013), 401–406.
33. Sathyasaikumar, K.V., Stachowski, E.K., Wonodi, I., Roberts, R.C., Rassoulpour, A., McMahon, R.P., Schwarcz, R., Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophr. Bull. 37:6 (2011), 1147–1156.
34. Schwarcz, R., Bruno, J.P., Muchowski, P.J., Wu, H.Q., Kynurenines in the mammalian brain: when physiology meets pathology. Nat. Rev. Neurosci. 13:7 (2012), 465–477.
35. Schwarcz, R., Rassoulpour, A., Wu, H.Q., Medoff, D., Tamminga, C.A., Roberts, R.C., Increased cortical kynurenate content in schizophrenia. Biol. Psychiatry 50:7 (2001), 521–530.
36. Schwieler, L., Larsson, M.K., Skogh, E., Kegel, M.E., Orhan, F., Abdelmoaty, S., Finn, A., Bhat, M., Samuelsson, M., Lundberg, K., Dahl, M.L., Sellgren, C., Schuppe-Koistinen, I., Svensson, C., Erhardt, S., Engberg, G., Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia-significance for activation of the kynurenine pathway. J. Psychiatry Neurosci. 40:2 (2015), 126–133.
37. Sellgren, C.M., Kegel, M.E., Bergen, S.E., Ekman, C.J., Olsson, S., Larsson, M., Vawter, M.P., Backlund, L., Sullivan, P.F., Sklar, P., Smoller, J.W., Magnusson, P.K., Hultman, C.M., Walther-Jallow, L., Svensson, C.I., Lichtenstein, P., Schalling, M., Engberg, G., Erhardt, S., Landen, M., A genome-wide association study of kynurenic acid in cerebrospinal fluid: implications for psychosis and cognitive impairment in bipolar disorder. Mol. Psychiatry, 2015.
38. Siever, L.J., Davis, K.L., The pathophysiology of schizophrenia disorders: perspectives from the spectrum. Am. J. Psychiatry 161:3 (2004), 398–413.
39. Soderlund, J., Olsson, S.K., Samuelsson, M., Walther-Jallow, L., Johansson, C., Erhardt, S., Landen, M., Engberg, G., Elevation of cerebrospinal fluid interleukin-1ss in bipolar disorder. J. Psychiatry Neurosci. 36:2 (2011), 114–118.
40. Soderlund, J., Schroder, J., Nordin, C., Samuelsson, M., Walther-Jallow, L., Karlsson, H., Erhardt, S., Engberg, G., Activation of brain interleukin-1beta in schizophrenia. Mol. Psychiatry 14:12 (2009), 1069–1071.
41. Stone, T.W., Neuropharmacology of quinolinic and kynurenic acids. Pharm. Rev. 45:3 (1993), 309–379.
42. Su, S., Snieder, H., Miller, A.H., Ritchie, J., Bremner, J.D., Goldberg, J., Dai, J., Jones, L., Murrah, N.V., Zhao, J., Vaccarino, V., Genetic and environmental influences on systemic markers of inflammation in middle-aged male twins. Atherosclerosis 200:1 (2008), 213–220.
43. Ting, K.K., Brew, B.J., Guillemin, G.J., Effect of quinolinic acid on human astrocytes morphology and functions: implications in Alzheimer's disease. J. Neuroinflamm., 6, 2009, 36.
44. Urata, Y., Koga, K., Hirota, Y., Akiyama, I., Izumi, G., Takamura, M., Nagai, M., Harada, M., Hirata, T., Yoshino, O., Kawana, K., Fujii, T., Osuga, Y., IL-1beta increases expression of tryptophan 2,3-dioxygenase and stimulates tryptophan catabolism in endometrioma stromal cells. Am. J. Reprod. Immunol. 72:5 (2014), 496–503.
45. Williams, J.B., A structured interview guide for the Hamilton depression Rating scale. Arch. Gen. Psychiatry 45:8 (1988), 742–747.
46. Young, R.C., Biggs, J.T., Ziegler, V.E., Meyer, D.A., A rating scale for mania: reliability, validity and sensitivity. Br. J. Psychiatry 133 (1978), 429–435.